TVTX

Travere Therapeutics Inc

TVTX.US travere.com + Research + Basket
CIK 0001438533
Employees 497
Phone 888 969 7879
Fiscal year end December
IPO Nov 08, 2012
Address 3611 Valley Centre Drive, San Diego, CA, United States, 92130
50.85
-0.04 (-0.07%)
USD · NASDAQ
52-week range
22.59
68.73
Trading at 61% of the 52-week range
Market Cap
4.73B
P/E Ratio
0.00
Forward P/E
33.33
Book Value
0.26
Div. Yield
N/A
% Institutions
116.05%
% Insiders
0.694%

1 Year

+70.6%

3 Year

+652.1%

10 Year

+169.7%
Description

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.

Actions

Add an action for TVTX.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Eric M. Dube Ph.D. President, CEO & Director 1973
Mr. Christopher Cline C.F.A. Chief Financial Officer 1985
Dr. William E. Rote Ph.D. Chief Research Officer 1963
Mr. Peter Heerma Chief Commercial Officer 1971
Dr. Jula Inrig M.D. Executive VP, Head of Research & Development and Chief Medical Officer 1975
Ms. Sandra Calvin SVP & Chief Accounting Officer 1966
Ms. Nivi Nehra Vice President of Corporate Communications & Investor Relations NA
Ms. Elizabeth E. Reed J.D. Chief Legal Officer, General Counsel & Secretary 1971
Ms. Angela Giannantonio Chief People Officer NA
Mr. Casey Logan Chief Business Officer NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Apr 22, 2026 William E Rote N/A Sale 9.10K $39.09 $355.72K SEC
Apr 15, 2026 Christopher R Cline N/A Sale 1.01K $42.61 $43.21K SEC
Apr 15, 2026 Elizabeth E Reed N/A Sale 6.79K $41.83 $283.82K SEC
Apr 15, 2026 Eric M Dube N/A Sale 64.00K $41.09 $2.63M SEC
Apr 15, 2026 Jula Inrig N/A Sale 1.02K $42.61 $43.38K SEC
Apr 14, 2026 Elizabeth E Reed N/A Sale 44.72K $41.21 $1.84M SEC
Apr 14, 2026 Jula Inrig N/A Sale 7.22K $41.93 $302.52K SEC
Apr 14, 2026 Christopher R Cline N/A Sale 7.25K $41.93 $303.91K SEC
Apr 14, 2026 Sandra Calvin N/A Sale 21.98K $41.07 $902.60K SEC
Apr 14, 2026 Gary A Lyons N/A Sale 8.00K $41.07 $328.56K SEC
Apr 14, 2026 Peter Heerma N/A Sale 7.22K $41.93 $302.52K SEC
Apr 14, 2026 Roy D Baynes N/A Sale 32.75K $41.29 $1.35M SEC
Apr 13, 2026 Christopher R Cline N/A Sale 65.00 $28.85 $1.88K SEC
Apr 06, 2026 Roy D Baynes N/A Sale 10.00K $33.00 $330.00K SEC
Apr 01, 2026 Eric M Dube N/A Sale 60.00K $30.93 $1.86M SEC
Apr 01, 2026 Elizabeth E Reed N/A Sale 10.00K $30.00 $300.00K SEC
Mar 16, 2026 Elizabeth E Reed N/A Sale 10.00K $28.09 $280.90K SEC
Feb 04, 2026 Jula Inrig N/A Sale 1.78K $32.21 $57.30K SEC
Feb 04, 2026 Christopher R Cline N/A Sale 1.75K $32.19 $56.17K SEC
Feb 04, 2026 Elizabeth E Reed N/A Sale 2.99K $32.18 $96.35K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
HHG PLC 11.42M Mar 31, 2026 12.11% $0.16 8.64%
Jupiter Topco LLC 11.32M Jun 30, 2026 12.01% $0.26 0.00%
BlackRock Inc 8.02M Jun 30, 2026 8.51% $0.01 2.93%
FMR Inc 7.10M Jun 30, 2026 7.53% $0.02 -35.30%
Bank of America Corp 4.57M Jun 30, 2026 4.85% $0.02 239.63%
State Street Corp 4.26M Jun 30, 2026 4.52% $0.01 -14.19%
Vanguard Capital Management, LLC 4.11M Jun 30, 2026 4.36% $0.01 1.55%
Perceptive Advisors LLC 3.75M Jun 30, 2026 3.98% $3.20 -9.41%
Delaware Management Holdings Inc 2.81M Jun 30, 2026 2.98% $0.24 -14.00%
Adage Capital Partners Gp LLC 2.57M Jun 30, 2026 2.73% $0.20 162.98%
Geode Capital Management, LLC 2.37M Jun 30, 2026 2.52% $0.01 0.10%
Rock Springs Capital Management LP 2.18M Jun 30, 2026 2.31% $6.04 47.44%
Kynam Capital Management, LP 2.00M Jun 30, 2026 2.12% $6.28 27.47%
Stephens Inv Mgmt Group LLC 1.88M Jun 30, 2026 1.99% $1.14 4.27%
Renaissance Technologies Corp 1.83M Jun 30, 2026 1.94% $0.14 -6.80%
Emerald Advisers, LLC 1.60M Jun 30, 2026 1.70% $2.14 2.81%
Armistice Capital, LLC 1.57M Jun 30, 2026 1.67% $1.09 -67.89%
Two Sigma Investments LLC 1.57M Jun 30, 2026 1.66% $0.06 3.81%
Vanguard Portfolio Management, LLC 1.54M Jun 30, 2026 1.64% $0.00 -9.80%
The Goldman Sachs Group Inc 1.54M Jun 30, 2026 1.63% $0.01 -10.72%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 2.96M 3.14% ▲ 0.28% Sep 30, 2026
2 iShares Russell 2000 ETF 2.31M 2.45% ▼ 1.14% Sep 30, 2026
3 State Street® SPDR® S&P® Biotech ETF 2.25M 2.38% ▼ 1.87% Sep 30, 2026
4 Nomura Small Cap Core I 1.57M 1.66% ▼ 12.01% Aug 31, 2026
5 Janus Henderson Global Life Sciences D 1.39M 1.47% ▼ 3.53% Aug 31, 2026
6 Vanguard Explorer Inv 1.36M 1.44% ▲ 8.07% Jun 30, 2026
7 Janus Global Life Science AUSD 1.33M 1.41% ▲ 0.51% Jun 30, 2026
8 Janus Henderson Glb Life Scn I2 USD 1.33M 1.41% ▼ 2.40% Aug 31, 2026
9 Janus Henderson Hrzn Biotec E2 USD 1.29M 1.37% ▲ 2.03% Jun 30, 2026
10 Janus Henderson Triton D 1.12M 1.19% ▲ 0.00% Aug 31, 2026

Financial Highlights

▼
Market Cap: $4.73B
EBITDA: $22.91M
Book Value: $0.26
Earnings/Share: $-0.74
Profit Margin: -7.35%
Operating Margin: 2.33%
ROA (TTM): -3.73%
ROE (TTM): -236.36%
Revenue (TTM): $591.33M
Revenue/Share (TTM): $6.48
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 48.20%

Valuation Metrics

Enterprise Value: $4.92B
Trailing P/E: 0.00
Forward P/E: 33.33

Shares Statistics

Shares Outstanding: 92.99M
Shares Float: 93.22M
% Insiders: 0.694%
% Institutions: 116.05%
Short % Float: 15.08%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$490.73M
Cost of Goods Sold
adjust
$-10.34M
Gross Profit
subtotal
$480.39M
SG&A
adjust
$-337.20M
R&D
adjust
$-206.01M
Operating Income
subtotal
$-62.82M
Other / Non-Operating Items
adjust
$37.28M
Net Income
subtotal
$-25.55M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about TVTX.US!